Pcsk9 acts as a chaperone for the ldl receptor in the endoplasmic reticulum

Biochemical Journal

Volumn 457, Issue 1, 2014, Pages 99-105

  Stroøm, Thea Bismo ^a   Tveten, Kristian ^a   Leren, Trond P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chaperone; Cholesterol; Endoplasmic reticulum; Low Density lipoprotein receptor; Proprotein convertase subtilisin kexin type 9 (PCSK9); Proteasome

Indexed keywords

COMPLEMENTARY DNA; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GAIN OF FUNCTION MUTATION; GENETIC TRANSFECTION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; WESTERN BLOTTING;

CATALYSIS; CELL MEMBRANE; ENDOPLASMIC RETICULUM; HEP G2 CELLS; HOMEOSTASIS; HUMANS; MOLECULAR CHAPERONES; PROPROTEIN CONVERTASES; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; PROTEIN PRECURSORS; PROTEIN TRANSPORT; PROTEOLYSIS; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84890053040     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20130930     Document Type: Article

References (36)

1. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A. and Chretien, M. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 100, 928-933
2. Maxwell, K. N. and Breslow, J. L. (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. U.S.A. 101, 7100-7105
3. Park, S. W., Moon, Y. A. and Horton, J. D. (2004) Post-transcriptional regulation of low density lipoprotein receptor by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279, 50630-50638
4. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C. and Hobbs, H. H. (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612
5. Goldstein, J. L., Hobbs, H. H. and Brown, M. S. (2001) Familial hypercholesterolemia. In The Metabolic and Molecular Basis of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S. and Valle, D., eds), pp. 2863-2914, McGraw-Hill, New York
6. Herbert, P. N., Assmann, G., Gotto, A. M. and Fredrickson, D. S. (1983) Familial lipoprotein deficiency: Aβ lipoproteinemia, hypolipoproteinemia and Tangier disease. In The Metabolic Basis of Inherited Disease (Stanbury, J. B., Wyngaarden, J. B., Fredrickson, D. S., Goldstein, J. L. and Brown, M. S., eds), pp. 589-621, McGraw-Hill, New York
7. Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D. and Deisenhofer, J. (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. U.S.A. 105, 1820-1825
8. Cameron, J., Holla, Oø.L., Berge, K. E., Kulseth, M. A., Ranheim, T., Leren, T. P. and Laerdahl, J. K. (2008) Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion. FEBS J. 275, 4121-4133
9. Holla, Oø.L., Cameron, J., Tveten, K., Stroøm, T. B., Berge, K. E., Laerdahl, J. K. and Leren, T. P. (2011) Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors. J. Lipid Res. 52, 1787-1794
10. Tveten, K., Holla, Oø.L., Cameron, J., Stroøm, T. B., Berge, K. E., Laerdahl, J. K. and Leren, T. P. (2012) Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification. Hum. Mol. Genet. 21, 1402-1409
11. Zhang, D. W., Garuti, R., Tang, W. J., Cohen, J. C. and Hobbs, H. H. (2008) Structuralrequirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 105, 13045-13050
12. Tveten, K., Stroøm, T. B., Berge, K. E. and Leren, T. P. (2013) PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment. J. Lipid Res. 54, 1560-1566
13. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C. and Hobbs, H. H. (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514-523
14. Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S. and Goldstein, J. L. (2003) Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U.S.A. 100, 12027-12032
15. Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E. and Breslow, J. L. (2003) Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44, 2109-2119
16. Jeong, H. J., Lee, H. S, Kim, K. S., Kim, Y. K., Yoon, D. and Park, S. W. (2008) Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J. Lipid Res. 49, 399-409
17. Hua, X., Yokoyama, C., Wu, J., Briggs, M. R., Brown, M. S., Goldstein, J. L. and Wang, X. (1993) SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl. Acad. Sci. U.S.A. 90, 11603-11607
18. Nassoury, N., Blasiole, D. A., Oler, A. T., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A. and Seidah, N. G. (2007) The cellular traficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718-732
19. Poirier, S., Mayer, G., Poupon, V., McPherson, P. S., Desjardins, R., Ly, K., Asselin, M. C., Day, R., Duclos, F. J., Witmer, M. et al. (2009) Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J. Biol. Chem. 284, 28856-28864
20. Holla, Oø.L., Cameron, J., Berge, K. E., Ranheim, T. and Leren, T. P. (2007) Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol. 8, 9
21. Sørensen, S., Ranheim, T., Bakken, K. S., Leren, T. P. and Kulseth, M. A. (2006) Retention of mutant low density lipoprotein receptor in endoplasmic reticulum (ER) leads to ER stress. J. Biol. Chem. 281, 468-476
22. Cameron, J., Holla, O. L., Laerdahl, J. K., Kulseth, M. A., Ranheim, T., Rognes, T., Berge, K. E. and Leren, T. P. (2008) Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J. Intern. Med. 263, 420-431
23. Tveten, K., Stroøm, T. B., Cameron, J., Holla, Oø.L., Berge, K. E. and Leren, T. P. (2012) Characterization of a naturally occurring degradation product of the LDL receptor. Mol. Genet. Metab. 105, 149-154
24. Choi, S., Park, S. Y., Kwak, D., Phark, S., Lee, M., Lim, J. Y., Jung, W. W. and Dul, D. (2010) Proteomic analysis of proteins secreted by HepG2 cells treated with butyl benzyl phthalate. J. Toxicol. Environ. Health 73, 1570-1585
25. Cameron, J., Holla, Oø.L., Ranheim, T., Kulseth, M. A., Berge, K. E. and Leren, T. P. (2006) Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15, 1551-1558
26. Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M. C., Varret, M., Allard, D., Trillard, M. et al. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865-48875
27. Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R. et al. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14, 413-419
28. Stroøm, T. B., Tveten, K., Holla, Oø.L., Cameron, J., Berge, K. E. and Leren, T. P. (2011) Characterization of residues in the cytoplasmic domain of the LDL receptor required for exit from the endoplasmic reticulum. Biochem. Biophys. Res. Commun. 415, 642-645
29. Cameron, J., Bogsrud, M. P., Tveten, K., Strøm, T. B., Holven, K., Berge, K. E. and Leren, T. P. (2012) Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways. Transl. Res. 160, 125-130
30. Raal, F., Panz, V., Immelman, A. and Pilcher, G. (2013) Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J. Am. Heart Assoc. 2, e000028
31. Bottomley, M. J., Cirillo, A., Orsatti, L., Ruggeri, L., Fisher, T. S., Santoro, J. C., Cummings, R. T., Cubbon, R. M., Lo Surdo, P., Calzetta, A. et al. (2009) Structural and biochemical characterization of the wild-type PCSK9-EGF(AB) complex and familial hypercholesterolemia mutants. J. Biol. Chem. 284, 1313-1323
32. Miura, H., Tomoda, H., Miura, K., Takishima, K. and Omura, S. (1996) Lactacystine increases LDL receptor level on HepG2 cells. Biochem. Biophys. Res. Commun. 227, 684-687
33. Henderson, B. (2010) Integrating the cell stress response: a new review of molecular chaperones as immunological and physiological homeostatic regulators. Cell Biochem. Funct. 28, 1-14
34. Henderson, B. and Pockley, A. G. (2012) Proteotoxic stress and circulating cell stress proteins in the cardiovascular diseases. Cell Stress Chaperones 17, 303-311
35. Li, W., Sahu, D. and Tsen, F. (2012) Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochim. Biophys. Acta 1823, 730-741
36. Pandit, S., Wisniewski, D., Santoro, J. C., Ha, S., Ramakrishnan, V., Cubbon, R. M., Cummings, R. T., Wright, S. D., Sparrow, C. P., Sitlani, A. and Fisher, T. S. (2008) Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. J. Lipid Res. 49, 1333-1343